

# **United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast, 2016 to 2022**

<https://marketpublishers.com/r/U48ED89384BEN.html>

Date: December 2016

Pages: 122

Price: US\$ 1,000.00 (Single User License)

ID: U48ED89384BEN

## **Abstracts**

United States Influenza Vaccine Market is expected to reach more than US\$ 2.5 Billion by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZeneca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the

forecast period. The report also entails major drivers and barriers of influenza vaccine market.

Major and Promising Vaccine covered in the report are as follows:

1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax

Key Companies Covered in the Report are as follows

1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZeneca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate

## Contents

### **1. EXECUTIVE SUMMARY**

### **2. UNITED STATES INFLUENZA VACCINE MARKET & FORECAST**

### **3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINE**

#### 3.1 Number of Children Vaccinated

#### 3.2 Number of Adults Vaccinated

### **4. UNITED STATES INFLUENZA VACCINE MARKET DRIVERS AND BARRIERS**

#### 4.1 Market Drivers

#### 4.2 Market Barriers

### **5. UNITED STATES INFLUENZA VACCINE PRODUCTION & DISTRIBUTION**

#### 5.1 Vaccine Choices Remain Available for Patients, Providers

#### 5.2 Influenza Vaccine Price Trends

##### 5.2.1 Pediatric Influenza Vaccine Price Trends

##### 5.2.2 Adult Influenza Vaccine Price Trends

#### 5.3 Influenza Vaccine Production, Supply, and Allocation

#### 5.4 Influenza Vaccine Distribution & Demand

#### 5.5 Influenza Vaccine Effectiveness

#### 5.6 Managing Influenza with Diagnostic Resources

#### 5.7 Distribution Method of Influenza Vaccination

### **6. UNITED STATES INFLUENZA VACCINE MARKET – REGULATORY LANDSCAPE**

### **7. MARKET DYNAMICS – MERGERS, ACQUISITIONS, KEY AGREEMENTS & COLLABORATIONS**

#### 7.1 Merger & Acquisitions

#### 7.2 Collaboration Deal

#### 7.3 Licensing, Exclusive & Distribution Agreement Deal

##### 7.3.1 Licensing Agreement

##### 7.3.2 Exclusive Agreement

### 7.3.3 Distribution Agreement

## **8. INFLUENZA VACCINE – PIPELINE ASSESSMENT**

### 8.1 Promising Vaccine in Clinical Development

### 8.2 Promising Vaccine in Early–Stage Development

## **9. INFLUENZA VACCINE – CLINICAL TRIALS ASSESSMENT BY PHASE AND TRIAL STATUS**

### 9.1 Year 2016

### 9.2 Year 2015

### 9.3 Year 2014

### 9.4 Year 2013

## **10. KEY COMPANIES ANALYSIS**

### 10.1 Sanofi Pasteur

#### 10.1.1 Business Overview

#### 10.1.2 Sanofi Pasteur – Influenza Vaccine Outlook

##### 10.1.2.1 Fluzone High–Dose Vaccine

##### 10.1.2.2 Fluzone Quadrivalent Vaccine

##### 10.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine

##### 10.1.2.4 Vaxigrip Vaccine

#### 10.1.3 Influenza Vaccine Sales Analysis

### 10.2 GlaxoSmithKline (GSK)

#### 10.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook

##### 10.2.1.1 Fluarix Quadrivalent

##### 10.2.1.2 Flulaval Quadrivalent

#### 10.2.2 Influenza Vaccine Sales Analysis & Forecast

### 10.3 AstraZeneca

#### 10.3.1 Business Overview

#### 10.3.2 AstraZeneca – Influenza Vaccine Outlook

##### 10.3.2.1 Fluenz Tetra/FluMist Quadrivalent

#### 10.3.3 Influenza Vaccine Sales Analysis

### 10.4 Protein Sciences Corporation

#### 10.4.1 Business Overview

#### 10.4.2 Protein Sciences Corporation – Influenza Vaccine Outlook

##### 10.4.2.1 Flublok

## 10.5 Seqirus (CSL Limited)

### 10.5.1 Business Overview

### 10.5.2 Seqirus – Influenza Vaccine Outlook

#### 10.5.2.1 Flucelvax Quadrivalent

#### 10.5.2.2 Afluria Quadrivalent

#### 10.5.2.3 Agrippal

#### 10.5.2.4 Fluad

#### 10.5.2.5 Fluvirin

#### 10.5.2.6 Fluvax

## List Of Tables

### LIST OF TABLES

Table 5–1: United States Influenza Vaccine Available,2016 –

Table 5–2: United States – Pediatric Influenza Vaccine Price, 2016 – 2017

Table 5–3: United States – Adult Influenza Vaccine Price, 2016 – 2017

Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation

Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017

Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016

Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015

Table 5–8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005 – 2016

Table 5–9: Managing Influenza with Diagnostic Resources

Table 5–10: Distribution of Influenza Vaccination

Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 7–1: Influenza Vaccine Market – Merger & Acquisitions (Million US\$),2003 – 2015

Table 7–2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016

Table 7–3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016

Table 7–4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016

Table 7–5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016

## List Of Figures

### LIST OF FIGURES

Figure 2 1: United States – Influenza Vaccine Market (Million US\$),2010 – 2015

Figure 2 2: United States – Forecast for Influenza Vaccine Market (Million US\$),2016 – 2022

Figure 3 1: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 3 2: United States – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 3 3: United States – Number of Children Vaccinated(Thousand),2010 – 2015

Figure 3 4: United States – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022

Figure 3 5: United States – Number of Adults Vaccinated(Thousand),2010 – 2015

Figure 3 6: United States – Forecast for Number of Adults Vaccinated(Thousand),2016 – 2022

Figure 5 1: United States – Influenza Vaccine Doses Distributed, By Season(Million),2010 – 2016

Figure 10 1: Sanofi Pasteur – Influenza Vaccine Net Sales (Million US\$),2011 – 2015

Figure 10 2: Sanofi Pasteur – Forecast for Influenza Vaccine Net Sales (Million US\$),2016 – 2022

Figure 10 3: GSK – Influenza Vaccine Net Sales (Million US\$),2011 – 2015

Figure 10 4: GSK – Forecast for Influenza Vaccine Net Sales (Million US\$),2016 – 2022

Figure 10 5: AstraZeneca – Influenza Vaccine Net Sales (Million US\$),2011 – 2015

## I would like to order

Product name: United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast, 2016 to 2022

Product link: <https://marketpublishers.com/r/U48ED89384BEN.html>

Price: US\$ 1,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U48ED89384BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970